Subgroup Analyses in Randomized Clinical Trials: Statistical and Regulatory Issues
Jean‐Marie Grouin, Maylis Coste, John A. Lewis · Journal of Biopharmaceutical Statistics · 2005
Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgroup analyses are still frequently questioned. This article provides guidance on when subgroup analyses can be done, when they should be done, and their interpretation. The validity of common regulatory claims based on subgroup analyses is then discussed.
Cited by 61 works. doi:10.1081/bip-200067988
Authors
References
- Biased Estimates of Treatment Effect in Randomized Experiments with Nonlinear Regressions and Omitted Covariates
- Points to Consider on Multiplicity Issues in Clinical Trials
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems
- Misspecified Proportional Hazard Models
- Statistical Issues in Drug Development
- Covariate imbalance and random allocation in clinical trials
- Testing for baseline balance in clinical trials
- Statistical Issues in Drug Development
- Some aspects of analysis of covariance.
- Statistical Considerations for Multiplicity in Confirmatory Protocols